JP2013538829A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538829A5
JP2013538829A5 JP2013530333A JP2013530333A JP2013538829A5 JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5 JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013530333 A JP2013530333 A JP 2013530333A JP 2013538829 A5 JP2013538829 A5 JP 2013538829A5
Authority
JP
Japan
Prior art keywords
agent
targeted delivery
conjugate
group
nanocarrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538829A (ja
JP5927194B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/052856 external-priority patent/WO2012040524A1/en
Publication of JP2013538829A publication Critical patent/JP2013538829A/ja
Publication of JP2013538829A5 publication Critical patent/JP2013538829A5/ja
Application granted granted Critical
Publication of JP5927194B2 publication Critical patent/JP5927194B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530333A 2010-09-24 2011-09-23 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート Expired - Fee Related JP5927194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38620110P 2010-09-24 2010-09-24
US61/386,201 2010-09-24
PCT/US2011/052856 WO2012040524A1 (en) 2010-09-24 2011-09-23 Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015210354A Division JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Publications (3)

Publication Number Publication Date
JP2013538829A JP2013538829A (ja) 2013-10-17
JP2013538829A5 true JP2013538829A5 (https=) 2014-10-09
JP5927194B2 JP5927194B2 (ja) 2016-06-01

Family

ID=44774137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013530333A Expired - Fee Related JP5927194B2 (ja) 2010-09-24 2011-09-23 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
JP2015210354A Pending JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015210354A Pending JP2016026205A (ja) 2010-09-24 2015-10-27 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Country Status (8)

Country Link
US (1) US20120082616A1 (https=)
EP (1) EP2618846A1 (https=)
JP (2) JP5927194B2 (https=)
KR (1) KR20130136983A (https=)
CN (1) CN103269722A (https=)
CA (1) CA2811601A1 (https=)
IL (1) IL225414A0 (https=)
WO (1) WO2012040524A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454220C2 (ru) * 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
KR101525132B1 (ko) * 2008-10-08 2015-06-02 포항공과대학교 산학협력단 Ｘ 선용 조영제 캡슐 및 이의 제조방법
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CN103476798B (zh) * 2011-04-15 2017-04-05 首尔大学校产学协力团 在粘合物质和可铁宁的粘合体上结合有抗‑可铁宁抗体的复合体及其用途
WO2013049405A1 (en) * 2011-09-30 2013-04-04 Mallinckrodt Llc Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers
RU2493848C1 (ru) * 2012-06-14 2013-09-27 Геннадий Петрович Власов Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты)
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
JP6527516B2 (ja) 2013-12-03 2019-06-05 ノースウェスタン ユニバーシティ リポソーム粒子、前述のものを作製する方法及びその使用
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
JP6595232B2 (ja) 2015-07-02 2019-10-23 ソニー・オリンパスメディカルソリューションズ株式会社 内視鏡用撮像装置、内視鏡装置、及び内視鏡用ケーブル
KR101704379B1 (ko) * 2015-10-27 2017-02-08 (주)알테오젠 항체-약물 접합체 및 그 제조방법
CN108697815A (zh) * 2016-02-10 2018-10-23 辉瑞公司 具有egfr配体的治疗性纳米颗粒及其制备和使用方法
KR101856838B1 (ko) * 2016-02-17 2018-06-19 이희정 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도
EP3452598A4 (en) * 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018213789A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Modified messenger rna comprising functional rna elements
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
US20190008987A1 (en) * 2017-07-07 2019-01-10 Drexel University Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs
CN107998080A (zh) * 2017-11-21 2018-05-08 东南大学 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法
JP7423521B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US20220265856A1 (en) 2017-11-22 2022-08-25 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
US11007211B2 (en) 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
CN110545794B (zh) * 2018-01-22 2021-02-26 北京茵诺医药科技有限公司 用于靶向活化cd44分子的胶束纳米载体递送系统、其制备方法和用途
KR101977532B1 (ko) * 2018-03-09 2019-05-10 연세대학교 원주산학협력단 약물, 양자점 및 표적화제를 포함하는 나노 마이셀 및 이의 용도
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
US20220243182A1 (en) 2018-09-13 2022-08-04 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
WO2020056147A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
WO2020056239A1 (en) 2018-09-14 2020-03-19 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP3856233A1 (en) 2018-09-27 2021-08-04 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
CN113906293A (zh) * 2019-05-31 2022-01-07 株式会社新日本科学 使用色谱质谱分析装置的质谱分析方法
CN110787149A (zh) * 2019-11-12 2020-02-14 深圳碳十四科技创新有限公司 双壳层纳米粒子及其制备方法
US20230235298A1 (en) 2020-06-01 2023-07-27 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2022038605A1 (en) * 2020-08-20 2022-02-24 Bionanosim (Bns) Ltd Lipid delivery systems for delivery of oxaliplatin palmitate acetate
AU2021377895A1 (en) 2020-11-13 2023-06-15 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
AU2023265915A1 (en) * 2022-05-05 2024-11-21 Aion Healthspan, Inc. Nanomaterial-stem cell compositions and methods of use
US20260035707A1 (en) 2022-07-26 2026-02-05 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024182301A2 (en) 2023-02-27 2024-09-06 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
EP4704816A1 (en) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
DE10049074A1 (de) 2000-10-02 2002-04-18 Andreas Kage Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren
WO2006078646A2 (en) 2005-01-18 2006-07-27 Caltagirone Gaetano T A class of supramolecular drug molecules and methods of identification and use thereof

Similar Documents

Publication Publication Date Title
JP2013538829A5 (https=)
He et al. Aptamer-based targeted drug delivery systems: current potential and challenges
Egusquiaguirre et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
JP5927194B2 (ja) 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート
Allen et al. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer
Mussi et al. Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics
US20150030541A1 (en) Nanoparticle peg modification with h-phosphonates
JP2014527071A5 (https=)
JP2014528411A5 (https=)
JP2015502946A5 (https=)
US20140234217A1 (en) Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers
Zanganeh et al. Immunoengineering in glioblastoma imaging and therapy
Yang et al. Chitosan hybrid nanoparticles as a theranostic platform for targeted doxorubicin/VEGF shRNA co-delivery and dual-modality fluorescence imaging
EP3258913A1 (en) Modified docetaxel liposome formulations and uses thereof
TWI760319B (zh) 乳癌治療
Yu et al. Surface modification of nanocarriers for cancer therapy
Grewal et al. New era of nanoparticles facilitated co-delivery in cancer therapy: two heads are better than one
Stanczyk et al. Dendrimers in therapy for breast and colorectal cancer
JP2014525459A5 (https=)
Zhu et al. Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma
EP3426306A1 (en) Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
US9216225B2 (en) Remote assembly of targeted nanoparticles using H-phosphate ENE/-YNE hydrophosphonylation reactions
Kim et al. Image-guided nanoparticle-based siRNA delivery for cancer therapy
Alavi et al. Nanocarrier system for increasing the therapeutic efficacy of oxaliplatin
Svenson Preclinical to clinical development of nanomedicines